Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

Abstract B-cell lymphoma is a group of hematological malignancies with high clinical and biological heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction between tumor cells and the tumor microenvironment (TME), which is composed of stromal cells and extracellular matrix....

Full description

Bibliographic Details
Main Authors: Yingyue Liu, Xiangxiang Zhou, Xin Wang
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:https://doi.org/10.1186/s13045-021-01134-x
id doaj-e6fa06da16fd4e19bcad4286cca4d1bc
record_format Article
spelling doaj-e6fa06da16fd4e19bcad4286cca4d1bc2021-08-22T11:03:39ZengBMCJournal of Hematology & Oncology1756-87222021-08-0114111710.1186/s13045-021-01134-xTargeting the tumor microenvironment in B-cell lymphoma: challenges and opportunitiesYingyue Liu0Xiangxiang Zhou1Xin Wang2Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong UniversityAbstract B-cell lymphoma is a group of hematological malignancies with high clinical and biological heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction between tumor cells and the tumor microenvironment (TME), which is composed of stromal cells and extracellular matrix. Although the roles of the TME have not been fully elucidated, accumulating evidence implies that TME is closely relevant to the origination, invasion and metastasis of B-cell lymphoma. Explorations of the TME provide distinctive insights for cancer therapy. Here, we epitomize the recent advances of TME in B-cell lymphoma and discuss its function in tumor progression and immune escape. In addition, the potential clinical value of targeting TME in B-cell lymphoma is highlighted, which is expected to pave the way for novel therapeutic strategies.https://doi.org/10.1186/s13045-021-01134-xTumor microenvironmentB-cell lymphomaImmunosuppressionTargeted therapy
collection DOAJ
language English
format Article
sources DOAJ
author Yingyue Liu
Xiangxiang Zhou
Xin Wang
spellingShingle Yingyue Liu
Xiangxiang Zhou
Xin Wang
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Journal of Hematology & Oncology
Tumor microenvironment
B-cell lymphoma
Immunosuppression
Targeted therapy
author_facet Yingyue Liu
Xiangxiang Zhou
Xin Wang
author_sort Yingyue Liu
title Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
title_short Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
title_full Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
title_fullStr Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
title_full_unstemmed Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
title_sort targeting the tumor microenvironment in b-cell lymphoma: challenges and opportunities
publisher BMC
series Journal of Hematology & Oncology
issn 1756-8722
publishDate 2021-08-01
description Abstract B-cell lymphoma is a group of hematological malignancies with high clinical and biological heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction between tumor cells and the tumor microenvironment (TME), which is composed of stromal cells and extracellular matrix. Although the roles of the TME have not been fully elucidated, accumulating evidence implies that TME is closely relevant to the origination, invasion and metastasis of B-cell lymphoma. Explorations of the TME provide distinctive insights for cancer therapy. Here, we epitomize the recent advances of TME in B-cell lymphoma and discuss its function in tumor progression and immune escape. In addition, the potential clinical value of targeting TME in B-cell lymphoma is highlighted, which is expected to pave the way for novel therapeutic strategies.
topic Tumor microenvironment
B-cell lymphoma
Immunosuppression
Targeted therapy
url https://doi.org/10.1186/s13045-021-01134-x
work_keys_str_mv AT yingyueliu targetingthetumormicroenvironmentinbcelllymphomachallengesandopportunities
AT xiangxiangzhou targetingthetumormicroenvironmentinbcelllymphomachallengesandopportunities
AT xinwang targetingthetumormicroenvironmentinbcelllymphomachallengesandopportunities
_version_ 1721200142486339584